The secondary and adverse eŠects when biguanides, alpha-glycosidase inhibitor or thiazolidine derivative was used with sulphonylurea agent (SU) as compared with those with SU alone in Type 2 diabetes patients by using Systematic Review. Two-agent concurrent treatment groups, taken from studies in which subjects were assigned to a group given only a sulfonylurea agent and a group given a sulfonylurea agent with the other glycemic control agent (combination of a sulfonylurea agent and a biguanide agent (I), combination of a sulfonylurea agent and an a-glucosidase inhibitor (II), and combination of a sulfonylurea agent and thiazolidinedione (III)), were studied in a randomized controlled trial. The secondary e‹cacy outcome measures were total cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, and change in body weight. The incidence of hypoglycemia, feeling of fullness, diarrhea, liver dysfunction, and edema was investigated as a safety outcome measure, and the clinical signiˆcance of concurrent treatment with a sulfonylurea agent in addition to the other glycemic control agent was investigated. With respect to (II), an antidiabetic eŠect was showed. As for (III), it had the disadvantage of increased body weight. Furthermore, increase of HDL-C levels, in particular, was observed. The improving eŠect of (III) on serum lipids may be clinically eŠective for considering the pathologic condition of diabetes, which is often complicated by hyperlipidemia.
INTRODUCTION
The chief goal of diabetes treatment is prevention of complications. Strict long-term glycemic control is key to achieving that goal. There are currentlyˆve types of oral antidiabetic agent available in Japan. In detail, biguanides (BG), which are used in obese diabetic patients, and sulphonylurea drugs (SU) are known to improve the long-term prognosis. SU, in particular, have been used in a clinical setting for many years, and the evidence supporting their eŠec-tiveness is clear. Moreover, it was reported that improvement in glycemic control resulted in a reduction in the risk of microvascular complications in the United Kingdom Prospective Diabetes Study (UKPDS). 1) 2) It has been reported that the risk of onset of diabetes increases in proportion to the duration of hyperglycemia, and that the lower the blood glucose level is, the lower the risk of onset will be. 3) If glycemic control is su‹ciently improved with oral antidiabetic agent, suggesting that concomitant therapy with such agents as the a-glycosidase inhibitor (AGI) have a potential to reduce the progression of diabetes as well as macro-and microvasucular complicatrions. 4) Many combinations of oral antidiabetic agents with diŠerent mechanisms of action have been reported to improve serum glucose, including the following eight: (1) SU＋BG, (2) SU＋AGI, (3) BG＋AGI, (4) SU＋thiazolidine derivative (TZD), (5) BG＋TZD, (6) AGI＋TZD (not covered by insurance), (7) AGI＋phenylalanine derivative, and (8) BG＋phenylalanine derivative (not covered by insurance). 5) However, with regard to selection of a second drug in patients using SU, the Evidence-based practice guideline for the treatment of diabetes in Japan 5) only states that patients should be started on a small dose of a single oral antidiabetic agent and that an agent with a diŠerent mechanism of action should be administered when satisfactory control cannot be achieved with an increased dose. It is well known that combination therapy intensiˆes a decrease in blood glucose. However, little attention has been given to the behavior of serum lipids and side eŠects when selecting a second agent. It is important to note that combination therapy aŠects the behavior of serum lipids in Type 2 diabetes patients.
In the present study, we systematically examined by means of systematic review the secondary eŠects when BG, AGI or TZD was used with SU as compared with those with SU alone in Type 2 diabetes patients.
METHOD
Randomized controlled trials (RCT) in patients with Type 2 diabetes in which subjects were assigned to a group given only SU and a group given SU plus another agent (combination of SU and BG (I), combination of SU and AGI (II), and combination of SU and TZD (III)) were systematically searched. The e‹cacy outcome measure was HbA1c. Secondary e‹cacies were evaluated by total cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, and change in body weight. For safety outcome measures, the incidence of hypoglycemia, feeling of fullness, diarrhea, edema, and liver damage was investigated as adverse reactions of (I) to (III) speciˆed in the Evidencebased practice guideline for the treatment of diabetes in Japan, 5) and the clinical signiˆcance of concurrent treatment with SU plus another agent was investigated.
For one endpoint, the results were integrated using meta-analysis, and e‹cacy and safety were evaluated.
Article Extraction Method Using PubMed Cochrane Library (CCTR/CENTRAL was used) as databases, RCT (articles in English) that investigated the e‹cacy of concomitant use of two oral antidiabetic agents in patients with Type 2 diabetes were systematically searched separately for (I) to (III). Articles in Japanese were extracted using the same search method as that used for English articles, using Japana Centra Revuo Medicina (January 1981-November 2004) as a database. Article Adoption Criteria Study Design RCT with a parallel or crossover design were used. In the case of trials with a crossover design, only the results of theˆrst half of the trial were used. Subjects Trials in which subjects had been diagnosed with Type 2 diabetes and underwent two-agent treatment with SU and AGI, TZD or BG were used.
Intervention Placebo-controlled RCT were used.
Endpoints
In terms of the primary endpoint, articles that included HbA1c as indicator used for evaluation of drug main e‹cacy were used. Secondary endpoints were change in body weight, TC, TG, LDL-C, and HDL-C.
Observation Period Trials with an observation period of at least 4 weeks and that measured the above-mentioned primary endpoints were used.
Language Articles written in a language other than Japanese or English were excluded from the analysis in the present study since they could not be understood by the investigators.
Data Using the scale of Jadad et al., 6) extracted articles were scored (maximum of 5 points) in terms of randomization, masking, and handling of dropouts in each clinical study, and the quality of articles was evaluated based on the total score.
Statistical Analysis (Meta-Analysis) Extracted articles underwent meta-analysis after they were classiˆed from the viewpoint of endpoints and duration of treatment, etc., and they were statistically evaluated based on the results.
When multiple articles were merged, the heterogeneity of articles to be analyzed wasˆrst evaluated using the Q-test (with degree of freedom of chi-square distribution of -1 of number of articles, p＜ 0.10). When the heterogeneity was rejected, aˆxed-eŠect model (Mantel-Haenszel test) was used. Although the heterogeneity was not rejected but it was believed to be possible to merge articles, a random-eŠect model (DerSimonian-Laird test) was used. The statistical analysis software used was Cochrane Review Manager 4.2.3. For meta-analysis related to evaluation of primary and secondary endpoints, calculations were expressed as the weighted mean diŠerence (WMD) by weighting the mean diŠerence between groups using more than one antidiabetic drug and groups using SU alone with the inverse distribution, using the WMD method.
With regard to evaluation of safety, the frequency (incidence) of adverse reactions was calculated as an odds ratio. 
RESULTS

Search and Extraction Results
A MEDLINE search of English-language articles yielded 238 reports (I), 55 reports (II), and 54 reports (III). Excluding duplications, the Cochrane Library (CCTR/ CENTRAL) yielded 8 reports (I). Of these, the number of articles that satisˆed the adoption criteria was 11 reports (I), 7 reports (II), and 11 reports (III). Articles excluded were those that compared two twoagent concomitant therapies, those that compared three-agent concomitant therapies, and those with a diŠerent study design. Three reports (I), 5 reports (II), and 5 reports (III) were included in the analysis after evaluation of the quality of each article by means of scoring using the scale of Jadad et al. 6) A Japana Centra Revuo Medicina search of Japanese-language articles yielded 19, 24, and 14 reports for (I), (I), and (III), respectively (same order hereafter), but the number of those that satised the adoption criteria was 0, 0, and 3, respectively. Articles excluded included those that were collections of commentaries, those that were records of proceedings, and those with a diŠerent study design. Consequently, in the case of (III), a total of 8 reports were of a high quality of 3 points or higher according to the scoring of Jadad et al. 6) The characteristics of the articles in (I), (II), and (III) included in the analysis are shown in Table 1 .
Meta-analysis Results
Main EŠect 1) Improvement in HbA1c Level after Concomitant Use
The number of articles with HbA1c level at completion of observation as an outcome measure was 3, 5, and 8 for (I), (II), and (III), respectively. Meta-analysis of HbA1c level was performed using the WMD method. In the case of (III), since the heterogeneity was not rejected by Q-test when articles were merged, a random-eŠect model (DerSimonian-Laird test) was used. In the case of (I) and (II), since the heterogeneity was rejected by Qtest, aˆxed-eŠect model (Mantel-Haenszel test) was used. The results of analysis showed that WMD and its 95％ conˆdence interval in concomitant therapy groups (I), (II), and (III) did not include 0, and a signiˆcant (P＜0.00001, P＜0.00001, P＜0.00001) improvement was found in HbA1c level compared with groups given SU alone ( Table 2) .
Secondary EŠects 1) Change in Body Weight after Concomitant Use
The number of articles with change in body weight at completion of observation as an outcome measure was 3, 1, and 3 for (I), (II), and (III), respectively. Meta-analysis of change in body weight was performed using the WMD method. For (III), since the heterogeneity was not rejected by Q-test when articles were merged, a random-eŠect model (DerSimonian-Laird test) was used. As for the result, 0 was included in merged WMD and its conˆdence interval range. Results of analysis of (I) and (III) showed a signiˆcant (P＝0.01, P＝0.00001) decrease in body weight in the groups given SU alone compared with the concomitant therapy groups ( Table  5) .
2) Change in TC Level after Concomitant Use Total cholesterol level as an outcome measure was 1, 1, and 7 for (I), (II), and (III), respectively. For study (III), since the heterogeneity was not rejected by Q-test, a random-eŠect model (DerSimonianLaird test) was used. As shown in Table 6 , the value of total cholesterol did not show a signiˆcant decrease (P＝0.45).
3) Change in TG Level during Concomitant Use The number of articles included in the analysis was 1, 1, and 7 for (I), (II), and (III), respectively. Therefore, meta-analysis was performed for (III), the heterogeneity was not rejected by Q-test for (III), and a N: Number of total patients. ■: Weighted mean diŠerence (WMD) for HbA1c, the size represents weight degree. ◆: Estimated value of WMD in the total, the size shows the number of objective patients relatively. ← or →: The value for 95％CI to exceed value (±4) of x-axis. random-eŠect model (DerSimonian-Laird test) was used. There was a signiˆcant diŠerence in TG level between SU alone and the concomitant therapy (P＝ 0.01). The concomitant therapy decreased TG level compared with SU alone (Table 5) .
4) Change in HDL-C Level during Concomitant Use
The number of articles was 2, 1, and 7 for (I), (II), and (III), respectively. In the case of (I) and (III), since the heterogeneity was rejected by Qtest, aˆxed-eŠect model (Mantel-Haenszel test) was used. The results showed no signiˆcant decrease in (I) (P＝0.73) and a signiˆcant (P＝0.00001) decrease in (III) in the groups given SU alone compared with the concomitant therapy groups ( Table  6 ).
5) Change in LDL-C Level during Concomitant Use
The number of articles that satisˆed the criteria was 1, 0, and 3 for (I), (II), and (III), respectively. For (III), since the heterogeneity was not rejected by Q-test, a random-eŠect model (DerSimonian-Laird test) was used. (III) straddled 0 and did not show a signiˆcant decrease (P＝0.650) (Table 7).
Risk of Onset of Adverse Reactions during Concomitant Therapy 1) Investigation of Bloating Sensation in (II) Two articles from (II) satisˆed the criteria. Since the heterogeneity was rejected by Q-test, aˆxed-eŠect model (Mantel-Haenszel test) was used. The results showed that a signiˆcant (P＝0.0008) increase in bloating sensation was seen in the concomitant therapy groups (Table 8) .
2) Investigation of Incidence of Diarrhea in (II) Two articles satisˆed the criteria. Since the heterogeneity was rejected by Q-test, aˆxed-eŠect model (Mantel-Haenszel test) was used. The results showed that a signiˆcant (P＝0.01) increase in onset of diarrhea was seen in the concomitant therapy groups (Table 9).
3) Investigation of Incidence of Hypoglycemia in (III)
Six articles satisˆed the criteria. Since the heterogeneity was not rejected by Q-test, a randomeŠect model (DerSimonian-Laird test) was used. The results showed that a signiˆcant (P＝0.00001) increase in onset of hypoglycemia was seen in the concomitant therapy groups (Table 10) .
4) Investigation of Edema in (III)
Five articles satisˆed the criteria. Since the heterogeneity was rejected by Q-test, aˆxed-eŠect model (MantelHaenszel test) was used. The results showed that a signiˆcant (P＝0.0001) increase in onset of edema was seen in the concomitant therapy groups (Table  11) .
5) Investigation of Risk of Hepatic Dysfunction in (III)
Three articles satisˆed the criteria. Since the heterogeneity was rejected by Q-test, aˆxed-eŠect model (Mantel-Haenszel test) was used. The results showed that no increase in onset of hepatic dysfunction was seen in the concomitant therapy groups (P＝ 0.83) ( Table 12) .
DISCUSSION
The results of the present meta-analysis showed that, in the case of (I), a antidiabetic action was seen, N: Number of total patients, n: number of harmful event. ■: Weighted mean diŠerence (WMD) for body weight, the size represents weight degree. ◆: Estimated value of WMD in the total, the size shows the number of objective patients relatively. N: Number of total patients, n: number of harmful event. ■: Weighted mean diŠerence (WMD) for body weight, the size represents weight degree. ◆: Estimated value of WMD in the total, the size shows the number of objective patients relatively. ← or →: The value for 95％CI to exceed value (0.1～10) of x-axis. but an increase in body weight was noted. In addition, it had a beneˆcial eŠect on serum lipid levels; in particular, a lowering eŠect on LDL-C was noted. In the case of (II), a decrease in HbA1c was seen. On the other hand, only one article investigated the eŠect on weight change and TG level, so it was not included in the meta-analysis. As for (III), a antidiabetic action greater than that with SU used alone was found, but it had the disadvantage of increased body weight. Furthermore, in terms of serum lipids, increased HDL-C levels were observed. This action of (III) to increase HDL-C may be clinically eŠective considering the pathologic condition of diabetes, which is often complicated by hyperlipidemia.
We investigated adverse eŠects associated with concomitant therapy with each agent (BG, AGI, TZD) given in the Evidence-based practice guideline for the treatment of diabetes in Japan. 5) In the case of (III), the risk of hypoglycemia increased signiˆcantly as a result of concomitant use. A signiˆcant diŠerence was not seen in terms of the risk of onset of hepatic impairment. However, a signiˆcant increase in the risk of developing edema was seen as a result of concomitant use.
It was shown that (I) caused weight gain, but it was believed to be because about 80 percent of the subjects in the articles included in the present analysis used glibenclamide as the SU. In general, use of BG is said to cause weight loss, but the opposite result was seen in this study. Therefore, attention should be paid to weight gain in the case of concomitant use with glibenclamide.
